The triplet combination of letrozole, abemaciclib, and metformin achieved an objective response rate (ORR) of 32% and a clinical benefit rate (CBR) of 60% in patients with ER-positive endometrioid endometrial cancer.
The median progression-free survival (PFS) was 19.4 months, with a 6-month PFS rate of 69.8%.
Significant activity was observed in tumors with CTNNB1 mutations, while no responses were seen in TP53-mutated cases.
A novel pharmacokinetic finding revealed a more than 3-fold increase in metformin exposure when co-administered with letrozole and abemaciclib.
Introduction: The Rationale for Vertical Pathway Inhibition in Endometrial Cancer
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
